MODULATION OF PLASMA CYTOKINES AND ITS ASSOCIATION WITH CLINICAL RESPONSE TO TREATMENT WITH THE JAK2-SELECTIVE INHIBITOR SAR302503 IN A PHASE 2 STUDY OF PATIENTS WITH MYELOFIBROSIS (MF)

被引：0
|
作者：
Talpaz, M. [1 ]
Jamieson, C. [2 ]
Gabrail, N. [3 ]
Lebedinsky, C. [4 ]
Liu, F. [4 ]
Cao, H. [4 ]
Tefferi, A. [5 ]
Pardanani, A. [5 ]
机构：
[1] Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA
[2] Moores UCSD Canc Ctr, Dept Med, La Jolla, CA USA
[3] Gabrail Canc Ctr, Canton, OH USA
[4] Sanofi Oncol, Cambridge, MA USA
[5] Mayo Clin, Div Hematol, Dept Internal Med, Rochester, MN USA
来源：
HAEMATOLOGICA | 2013年 / 98卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P272
引用
收藏
页码：117 / 117
页数：1
相关论文
共 50 条
  • [1] Modulation of plasma cytokines and its association with clinical response to treatment with the JAK2-selective inhibitor SAR302503 in myelofibrosis (MF)
    Talpaz, Moshe
    Jamieson, Catriona H. M.
    Gabrail, Nashat Y.
    Lebedinsky, Claudia
    Liu, Feng
    Cao, Hui
    Tefferi, Ayalew
    Pardanani, Animesh Dev
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [2] A phase 2 randomized dose-ranging study of the JAK2-selective inhibitor fedratinib (SAR302503) in patients with myelofibrosis
    A Pardanani
    A Tefferi
    C Jamieson
    N Y Gabrail
    C Lebedinsky
    G Gao
    F Liu
    C Xu
    H Cao
    M Talpaz
    Blood Cancer Journal, 2015, 5 : e335 - e335
  • [3] A phase 2 randomized dose-ranging study of the JAK2-selective inhibitor fedratinib (SAR302503) in patients with myelofibrosis
    Pardanani, A.
    Tefferi, A.
    Jamieson, C.
    Gabrail, N. Y.
    Lebedinsky, C.
    Gao, G.
    Liu, F.
    Xu, C.
    Cao, H.
    Talpaz, M.
    BLOOD CANCER JOURNAL, 2015, 5 : e335 - e335
  • [4] Updated results from a randomized phase II dose-ranging study of the JAK2-selective inhibitor SAR302503 in patients with myelofibrosis (MF)
    Pardanani, Animesh Dev
    Jamieson, Catriona H. M.
    Gabrail, Nashat Y.
    Lebedinsky, Claudia
    Gao, Guozhi
    Patki, Abhay
    Liu, Feng
    Tefferi, Ayalew
    Talpaz, Moshe
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [5] Effect Of Treatment With The JAK2-Selective Inhibitor Fedratinib (SAR302503) On Bone Marrow Histology In Patients With Myeloproliferative Neoplasms With Myelofibrosis
    Jamieson, Catriona H. M.
    Hasserjian, Robert P.
    Gotlib, Jason
    Cortes, Jorge E.
    Stone, Richard M.
    Talpaz, Moshe
    Thiele, Juergen
    Rodig, Scott
    Patki, Abhay
    Wu, Kaida
    Wu, Jingyang
    Pozdnyakova, Olga
    BLOOD, 2013, 122 (21)
  • [6] Results Of a Randomized, Double-Blind, Placebo-Controlled Phase III Study (JAKARTA) Of The JAK2-Selective Inhibitor Fedratinib (SAR302503) In Patients With Myelofibrosis (MF)
    Pardanani, Animesh
    Harrison, Claire N.
    Cortes, Jorge E.
    Cervantes, Francisco
    Mesa, Ruben A.
    Milligan, Donald
    Masszi, Tamas
    Mishchenko, Elena
    Jourdan, Eric
    Vannucchi, Alessandro M.
    Drummond, Mark
    Jurgutis, Mindaugas
    Kuliczkowski, Kazimierz
    Gheorghita, Emanuil
    Passamonti, Francesco
    Neumann, Frank
    Gao, Guozhi
    Tefferi, Ayalew
    BLOOD, 2013, 122 (21)
  • [7] LONG-TERM FOLLOW UP OF A PHASE 1/2 STUDY OF SAR302503, AN ORAL JAK2 SELECTIVE INHIBITOR, IN PATIENTS WITH MYELOFIBROSIS (MF)
    Gotlib, J.
    Pardanani, A.
    Jamieson, C.
    Cortes, J.
    Talpaz, M.
    Stone, R.
    Gao, G.
    Zhang, J.
    Neumann, F.
    Lebedinsky, C.
    Tefferi, A.
    HAEMATOLOGICA, 2012, 97 : 145 - 145
  • [8] UPDATED RESULTS FROM A RANDOMIZED PHASE 2 DOSE-RANGING STUDY OF THE JAK2-SELECTIVE INHIBITOR SAR302503 IN PATIENTS WITH INTERMEDIATE-2 OR HIGH-RISK MYELOFIBROSIS (MF)
    Talpaz, M.
    Jamieson, C.
    Gabrail, N.
    Lebedinsky, C.
    Gao, G.
    Patki, A.
    Lui, F.
    Tefferi, A.
    Pardanani, A.
    HAEMATOLOGICA, 2013, 98 : 458 - 458
  • [9] A Phase II Randomized Dose-Ranging Study of the JAK2-Selective Inhibitor SAR302503 in Patients with Intermediate-2 or High-Risk Primary Myelofibrosis (MF), Post-Polycythemia Vera (PV) MF, or Post-Essential Thrombocythemia (ET) MF
    Talpaz, Moshe
    Jamieson, Catriona
    Gabrail, Nashat Y.
    Lebedinsky, Claudia
    Gao, Guozhi
    Liu, Feng
    Tefferi, Ayalew
    Pardanani, Animesh
    BLOOD, 2012, 120 (21)
  • [10] Effect of Food on the Bioavailability and Tolerability of the JAK2-Selective Inhibitor Fedratinib (SAR302503): Results From Two Phase I Studies in Healthy Volunteers
    Zhang, Meng
    Xu, Christine
    Ma, Lei
    Shamiyeh, Elias
    Yin, Jianyun
    von Moltke, Lisa L.
    Smith, William B.
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2015, 4 (04): : 315 - 321
12345